Overview

Intralesional PV-10 Chemoablation of Metastatic Melanoma

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the safety of intralesional (IL) PV-10 for the treatment of metastatic melanoma. This study will also include a preliminary assessment of response of treated and untreated lesions by clinical evaluation at follow-up of 12 to 24 weeks following IL PV-10 treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Provectus Pharmaceuticals